What is Advanced Accelerator Applications?
Founded in 2002 and headquartered in Saint-Genis-Pouilly, France, Advanced Accelerator Applications operates as a specialized pharmaceutical group dedicated to the development of nuclear medicine. The company maintains a comprehensive footprint across the three primary segments of the industry: diagnostic imaging, therapeutic radiopharmaceuticals, and molecular research. Their portfolio addresses high-unmet-need areas, including oncology, cardiology, and infectious diseases, positioning them as a pivotal player in the shift toward personalized, targeted therapy. By focusing on the intersection of molecular biology and nuclear medicine, the company provides clinicians with the tools necessary for early detection and precise treatment monitoring, effectively bridging the gap between diagnostic imaging and therapeutic intervention.
How much funding has Advanced Accelerator Applications raised?
Advanced Accelerator Applications has raised a total of $131.4M across 2 funding rounds:
Unspecified
$56.4M
Stock Offering
$75M
Unspecified (2014): $56.4M with participation from HBM Healthcare Investments
Stock Issuance/Offering (2015): $75M, investors not publicly disclosed
Key Investors in Advanced Accelerator Applications
HBM Healthcare Investments
HBM Healthcare Investments is a publicly traded investment firm focused on the global healthcare sector, managing a diversified portfolio of private and public companies to capture growth in medical innovation.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Advanced Accelerator Applications?
With the recent influx of capital, Advanced Accelerator Applications is poised to accelerate its pipeline of late-stage clinical trials and expand its manufacturing capabilities to meet global demand. The strategic focus will likely shift toward scaling the commercialization of its lead therapeutic candidates while simultaneously investing in next-generation diagnostic tracers. As the company matures, it remains well-positioned to capitalize on the increasing global demand for precision oncology, potentially exploring further strategic partnerships or acquisitions to bolster its intellectual property portfolio and maintain its competitive edge in the rapidly evolving radiopharmaceutical market.
See full Advanced Accelerator Applications company page
